These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36758003)

  • 21. Social Determinants of Health and Geographic Variation in Medicare per Beneficiary Spending.
    Zhang Y; Li J; Yu J; Braun RT; Casalino LP
    JAMA Netw Open; 2021 Jun; 4(6):e2113212. PubMed ID: 34110394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
    Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
    JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spending on and Use of Clinician-Administered Drugs in Medicare.
    Hyland MF; Sachs RM; Robillard L; Hayford TB; Bai G
    JAMA Health Forum; 2023 Sep; 4(9):e232941. PubMed ID: 37682554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
    Sheingold S; Nguyen NX
    Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Federal and Individual Spending on the 10 Costliest Medications in Medicare Part D from 2011 to 2015.
    Watanabe JH; Chau DL; Hirsch JD
    J Am Geriatr Soc; 2018 Aug; 66(8):1621-1624. PubMed ID: 29972589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in and Factors Contributing to the Slowdown in Medicare Spending Growth, 2007-2018.
    Buntin MB; Freed SS; Lai P; Lou K; Keohane LM
    JAMA Health Forum; 2022 Dec; 3(12):e224475. PubMed ID: 36459161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
    Raimond VC; Feldman WB; Rome BN; Kesselheim AS
    Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Five-year impact of Medicare Part D coverage gap reform on drug expenditures and utilization.
    Park J; Look KA
    Health Serv Res; 2022 Feb; 57(1):56-65. PubMed ID: 33870486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prescription drug spending and hospital use among Medicare beneficiaries with heart failure.
    McGee BT; Higgins MK; Phillips V; Butler J
    Res Social Adm Pharm; 2020 Oct; 16(10):1452-1458. PubMed ID: 31953113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spending and Utilization on Drugs Prescribed by Otolaryngologists to Medicare Beneficiaries, 2013 to 2017.
    Shah SA; Miller LE; Xiao R; Workman A; Xu L; Rathi VK
    Ann Otol Rhinol Laryngol; 2022 Sep; 131(9):987-996. PubMed ID: 34628959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Beneficiary-Level Risk Factors and Hospital-Level Characteristics With Medicare Part B Drug Spending Differences Between 340B and Non-340B Hospitals.
    Li Y; Xu S
    JAMA Netw Open; 2022 Feb; 5(2):e220045. PubMed ID: 35179584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
    Cortese BD; Dusetzina SB; Luckenbaugh AN; Al Hussein Al Awamlh B; Stimson CJ; Barocas DA; Penson DF; Chang SS; Talwar R
    J Clin Oncol; 2023 Oct; 41(29):4664-4668. PubMed ID: 37290029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
    Hayford TB
    JAMA Health Forum; 2024 May; 5(5):e241188. PubMed ID: 38787543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
    Blumberg DM; Prager AJ; Liebmann JM
    JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Why Does the Inflation Reduction Act Exclude Expensive Cancer Treatments in Price Negotiations?
    Horn DM; Jacobson M; Alpert AE; Duggan MG
    JCO Oncol Pract; 2024 Feb; 20(2):254-261. PubMed ID: 38060993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generic Drug Price Hikes And Out-Of-Pocket Spending For Medicare Beneficiaries.
    Joyce G; Henkhaus LE; Gascue L; Zissimopoulos J
    Health Aff (Millwood); 2018 Oct; 37(10):1578-1586. PubMed ID: 30273018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association Between Drug Characteristics and Manufacturer Spending on Direct-to-Consumer Advertising.
    DiStefano MJ; Markell JM; Doherty CC; Alexander GC; Anderson GF
    JAMA; 2023 Feb; 329(5):386-392. PubMed ID: 36749334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Geographic Variation in Medicare Fee-for-Service Health Care Expenditures Before and After the Passage of the Affordable Care Act.
    Sood N; Yang Z; Huckfeldt P; Escarce J; Popescu I; Nuckols T
    JAMA Health Forum; 2021 Dec; 2(12):e214122. PubMed ID: 35977300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.
    Dusetzina SB; Keating NL
    J Clin Oncol; 2016 Feb; 34(4):375-80. PubMed ID: 26644524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
    Dickson SR; Kent T
    JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.